Literature DB >> 5329432

Myasthenia gravis as an autoimmune disease: clinical aspects.

J A Simpson.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1966        PMID: 5329432     DOI: 10.1111/j.1749-6632.1966.tb45499.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


× No keyword cloud information.
  18 in total

1.  Cellular immune response to acetylcholine receptor-rich fraction, in patients with myasthenia gravis.

Authors:  O Abramsky; A Aharonov; C Webb; S Fuchs
Journal:  Clin Exp Immunol       Date:  1975-01       Impact factor: 4.330

Review 2.  Progress in myasthenia gravis.

Authors:  C W Havard
Journal:  Br Med J       Date:  1977-10-15

Review 3.  [The pathogenesis of myasthenia gravis as an immunological problem].

Authors:  J R Kalden
Journal:  Klin Wochenschr       Date:  1970-01-01

4.  Myasthenia gravis, haemolytic anaemia, and lymphoreticular malignancy.

Authors:  E B Silberstein
Journal:  Br Med J       Date:  1970-08-22

5.  T and B lymphocytes in myasthenia gravis.

Authors:  Y Itoyama; S Kawanami; I Goto; Y Kuroiwa
Journal:  Clin Exp Immunol       Date:  1979-09       Impact factor: 4.330

6.  The immunological effects of thymectomy in myasthenia gravis.

Authors:  G K Scadding; H C Thomas; C W Havard
Journal:  Clin Exp Immunol       Date:  1979-05       Impact factor: 4.330

7.  Leucocyte migration inhibition in myasthenia gravis. The effect of thymectomy.

Authors:  S Kawanami; Y Itoyama; Y Kuroiwa
Journal:  J Neurol       Date:  1976-07-15       Impact factor: 4.849

8.  Myasthenia gravis: brief guide to diagnosis and management.

Authors:  C Herrmann
Journal:  Calif Med       Date:  1967-04

9.  The role of radiation therapy in myasthenia gravis.

Authors:  T L Phillips; F Buschke
Journal:  Calif Med       Date:  1967-04

10.  A membrane-associated autoantibody in a case of myasthenia gravis with chronic hepatitis.

Authors:  A J Fairfax; D Doniach; C E Wells
Journal:  Clin Exp Immunol       Date:  1976-09       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.